Bioventus Inc. (NASDAQ: BVS) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 16.77 | EPS (ttm) | 0.77 | Insider Own | 29.64% | Shs Outstand | 67.75M | Perf Week | -0.54% |
| Market Cap | 874.63M | Forward P/E | 14.03 | EPS next Y | 0.92 | Insider Trans | 0.00% | Shs Float | 46.69M | Perf Month | -12.06% |
| Enterprise Value | 1.11B | PEG | 1.39 | EPS next Q | 0.17 | Inst Own | - | Short Float | 5.53% | Perf Quarter | 48.22% |
| Income | 54.00M | P/S | 1.50 | EPS this Y | 1.15% | Inst Trans | - | Short Ratio | 3.53 | Perf Half Y | 43.44% |
| Sales | 582.00M | P/B | 3.16 | EPS next Y | 18.17% | ROA | 8.09% | Short Interest | 2.58M | Perf YTD | 73.52% |
| Book/sh | 4.09 | P/C | 30.16 | EPS next 5Y | 12.10% | ROE | 28.39% | 52W High | 15.89 -18.75% | Perf Year | 86.29% |
| Cash/sh | 0.43 | P/FCF | 9.33 | EPS past 3/5Y | - -5.59% | ROIC | 11.37% | 52W Low | 6.26 106.23% | Perf 3Y | 316.45% |
| Dividend Est. | - | EV/EBITDA | 12.06 | Sales past 3/5Y | 3.52% 12.09% | Gross Margin | 68.00% | Volatility | 3.85% 3.35% | Perf 5Y | -12.06% |
| Dividend TTM | - | EV/Sales | 1.91 | EPS Y/Y TTM | 248.08% | Oper. Margin | 10.63% | ATR (14) | 0.55 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.17 | Sales Y/Y TTM | 1.57% | Profit Margin | 9.36% | RSI (14) | 43.12 | Recom | 2.29 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.69 | EPS Q/Q | 4.76% | SMA20 | -5.28% | Beta | 0.68 | Target Price | 18.33 |
| Payout | 0.00% | Debt/Eq | 1.36 | Sales Q/Q | 3.38% | SMA50 | -2.99% | Rel Volume | 1.18 | Prev Close | 12.63 |
| Employees | 950 | LT Debt/Eq | 1.28 | Earnings | Nov 03 | SMA200 | 29.50% | Avg Volume | 700.70K | Price | 12.91 |
| IPO Date | Feb 11, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.72% -1.44% | Net Debt/EBITDA | 2.52 | Volume | 828,232 | Change | 2.22% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-17-26 | Reiterated | Canaccord Genuity | Buy | $15 → $19 |
| Aug-06-26 | Reiterated | Craig-Hallum | Buy | $16 → $18 |
| Aug-06-26 | Reiterated | Barrington | Outperform | $14 → $18 |
| Jun-16-26 | Reiterated | Canaccord Genuity | Buy | $12 → $15 |
| Feb-09-26 | Initiated | Barrington | Outperform | $13 |
| May-07-25 | Reiterated | Craig-Hallum | Buy | $17 → $15 |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral | |
| Oct-01-24 | Reiterated | Canaccord Genuity | Buy | $8.00 → $12 |
| Aug-07-24 | Reiterated | Craig-Hallum | Buy | $9.00 → $12 |
| Mar-13-24 | Reiterated | Craig-Hallum | Buy | $9.00 |
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company’s product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company’s restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/6/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 582 | 568 | 573 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 186 | 186 | 185 | — | — | — | — | — | — | |
| Gross Profit | 396 | 382 | 388 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 322 | 312 | 327 | — | — | — | — | — | — | |
| Research and Development | 11 | 12 | 14 | — | — | — | — | — | — | |
| Other Operating Expense | 2 | 0 | 59 | — | — | — | — | — | — | |
| Operating Income | 62 | 59 | -12 | — | — | — | — | — | — | |
| Interest Expense | 19 | 26 | 39 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -3 | -6 | 2 | — | — | — | — | — | — | |
| Net Income Before Taxes | 39 | 26 | -49 | — | — | — | — | — | — | |
| Income Taxes | -22 | -2 | -5 | — | — | — | — | — | — | |
| Consolidated Net Income | 54 | 23 | -34 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 61 | 27 | -44 | — | — | — | — | — | — | |
| Net Income | 54 | 23 | -34 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.80 | 0.34 | -0.52 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.80 | 0.34 | -0.52 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.77 | 0.33 | -0.52 | — | — | — | — | — | — | |
| EBITDA | 92 | 99 | 39 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 16.77 | 22.55 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.51 | 0.88 | 1.19 | — | — | — | — | — | — | |
| Gross Margin | 68.04 | 67.25 | 67.71 | — | — | — | — | — | — | |
| Operating Margin | 10.65 | 10.39 | -2.09 | — | — | — | — | — | — | |
| Net Margin | 9.28 | 4.05 | -5.93 | — | — | — | — | — | — | |
| Shares Outstanding | 68 | 67 | 65 | — | — | — | — | — | — | |
| Market Capitalization | 878 | 498 | 683 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| SUTTER MARTIN P | director, 10 percent owner: | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 117,523 | Jun 04 |
| NOHRA GUY P | Director | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 148,892 | Jun 04 |
| Bartholdson John A. | director, 10 percent owner: | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 111,902 | Jun 04 |
| HAWKINS WILLIAM A | Director | Jun 02 '26 | Option Exercise | 0.00 | 39,789 | 0 | 297,640 | Jun 04 |
| STALNECKER SUSAN M | Director | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 138,239 | Jun 04 |
| Ladone Mary Kay | Director | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 111,263 | Jun 04 |
| Cowdy Philip G. | Director | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 43,982 | Jun 04 |
| McMurry-Heath Michelle | Director | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 77,279 | Jun 04 |
| Beyer Pat | Director | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 108,718 | Jun 04 |
| NEELS GUIDO J | Director | Jun 02 '26 | Option Exercise | 0.00 | 32,282 | 0 | 117,523 | Jun 04 |
| CHURCH KATRINA J | SVP & Chief Compliance Officer | Apr 10 '26 | Option Exercise | 0.00 | 4,300 | 0 | 66,032 | Apr 14 |
| D'Adamio Anthony | SVP & General Counsel | Apr 10 '26 | Option Exercise | 0.00 | 9,925 | 0 | 157,967 | Apr 14 |
| Singleton Mark Leonard | SVP & CFO | Apr 10 '26 | Option Exercise | 0.00 | 13,000 | 0 | 182,981 | Apr 14 |
| Singleton Mark Leonard | SVP & CFO | Mar 20 '26 | Option Exercise | 0.00 | 18,625 | 0 | 178,072 | Mar 24 |
| Singleton Mark Leonard | SVP & CFO | Mar 13 '26 | Option Exercise | 0.00 | 13,500 | 0 | 165,312 | Mar 17 |